Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NBI-1065890 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| NBI-1065890 | EXPERIMENTAL | Participants will receive NBI-1065890. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matching NBI-1065890. |
| Name | Type | Description |
|---|---|---|
| NBI-1065890 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
Key Inclusion Criteria: * Medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD) as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for at least 3 months prior to screening. * Medical...
NBI-1065890 is an investigational small molecule being developed for the treatment of tardive dyskinesia, a neurological condition characterized by involuntary movements. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
NBI-1065890 targets the vesicular monoamine transporter 2 (VMAT2), a protein involved in the packaging and release of neurotransmitters. By modulating VMAT2 activity, the drug aims to address the abnormal movements associated with tardive dyskinesia.
NBI-1065890 is being developed by Neurocrine Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol NBIX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with tardive dyskinesia.
NBI-1065890 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is designed to assess its efficacy, safety, and tolerability in adults with tardive dyskinesia.
NBI-1065890 is being evaluated in a Phase 2 clinical trial registered as NCT07365462. This randomized, double-blind, placebo-controlled study is recruiting approximately 100 adults with tardive dyskinesia in the United States to compare the drug against placebo.
NBI-1065890 is a distinct investigational compound targeting VMAT2. While other VMAT2 inhibitors exist for tardive dyskinesia, NBI-1065890 is a separate drug candidate developed by Neurocrine Biosciences. No alternative names for NBI-1065890 have been disclosed.